Next Article in Journal
Tear Film Steroid Profiling in Dry Eye Disease by Liquid Chromatography Tandem Mass Spectrometry
Next Article in Special Issue
Oral Supplementation of Melatonin Protects against Fibromyalgia-Related Skeletal Muscle Alterations in Reserpine-Induced Myalgia Rats
Previous Article in Journal
Cotton Ascorbate Oxidase Promotes Cell Growth in Cultured Tobacco Bright Yellow-2 Cells through Generation of Apoplast Oxidation
Previous Article in Special Issue
Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans
Open AccessArticle

New MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists

1
Pôle d’Expertise Biotechnologie, Chimie, Biologie, Institut de Recherches SERVIER, 78290 Croissy-sur-Seine, France
2
Pôle d’Expertise Recherches & BioPharmacie, Institut de Recherches Internationales SERVIER, 92150 Suresnes, France
3
DIVERCHIM S.A., 95700 Roissy-en-France, France
4
Pôle d’Innovations Thérapeutiques en Neurosciences, Institut de Recherches, SERVIER, 78290 Croissy-sur-Seine, France
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2017, 18(7), 1347; https://doi.org/10.3390/ijms18071347
Received: 26 March 2017 / Revised: 2 June 2017 / Accepted: 20 June 2017 / Published: 23 June 2017
(This article belongs to the Special Issue Melatonin and Its Analogues: Experimental and Clinical Aspects)
The search for melatonin receptor agonists and antagonists specific towards one of the receptor subtypes will extend our understanding of the role of this system in relaying circadian information to the body. A series of compounds derived from a hit compound discovered in a screening process led to powerful agonists specific for one of the isoform of the melatonin receptor namely, MT2. The compounds are based on a poorly explored skeleton in the molecular pharmacology of melatonin. By changing the steric hindrance of one substituent (i.e., from a hydrogen atom to a tributylstannyl group), we identified a possible partial agonist that could lead to antagonist analogues. The functionalities of these compounds were measured with a series of assays, including the binding of GTPγS, the inhibition of the cyclic AMP production, the β-arrestin recruitment, and the cell shape changes as determined by cellular dielectric spectroscopy (CellKey®). The variations between the compounds are discussed. View Full-Text
Keywords: molecular pharmacology; melatonin receptors; agonist; partial agonist; functional assays molecular pharmacology; melatonin receptors; agonist; partial agonist; functional assays
Show Figures

Graphical abstract

MDPI and ACS Style

Boutin, J.A.; Bonnaud, A.; Brasseur, C.; Bruno, O.; Lepretre, N.; Oosting, P.; Coumailleau, S.; Delagrange, P.; Nosjean, O.; Legros, C. New MT2 Melatonin Receptor-Selective Ligands: Agonists and Partial Agonists. Int. J. Mol. Sci. 2017, 18, 1347.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop